-transparent.png){kind=logo}
We present a case of well-differentiated follicular carcinoma of the thyroid with hyperfunctioning metastases and clinical thyrotoxicosis. The recommended I-131 treatment dose for patients with widespread bone metastases from thyroid carcinoma is 200 mCi. However, in a patient with hyperfunctioning metastatic tumor and increased radioiodine uptake, the treatment dose should be modified. Radiation dosimetry measurements performed on the patient in this study demonstrated that 132 mCi would be a safe therapeutic I-131 dose which would avoid injury to normal radiosensitive tissues. Consequently, she was given a 130-mCi therapeutic dose.
Related Publications
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
April 1951,
British medical journal,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
June 1961,
Canadian Medical Association journal,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
June 1950,
Nederlands tijdschrift voor geneeskunde,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
March 1961,
New York state journal of medicine,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
January 1952,
British medical bulletin,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
July 1950,
Journal of the American Medical Association,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
January 1978,
L'union medicale du Canada,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
September 1959,
Suomen laakarilehti. Finlands lakartidning,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
January 1961,
Problemy endokrinologii i gormonoterapii,
R Smith, and
C Blum, and
R S Benua, and
R A Fawwaz
January 1956,
Duodecim; laaketieteellinen aikakauskirja,
